Effect of transamniotic administration of epidermal growth factor on fetal rabbit small intestinal nutrient transport and disaccharidase development.
As fetal swallowing is documented in utero, supplementation of the ingested amniotic fluid with nutrients or hormones has been postulated as a potential prenatal treatment for intrauterine growth retardation (IUGR). To study the effect of epidermal growth factor (EGF) on the developing fetal small intestine, 12 pregnant rabbits underwent operation on day 24 of a normal 31-day gestation. Bilateral ovarian end fetuses underwent catheterization of their respective amniotic cavities with attachment to a miniosmotic pump. Study fetuses received recombinant human EGF at approximately 300 micrograms/kg/d for 1 week; controls received carrier solution only at an equivalent rate. On gestational day 31, fetuses were delivered by cesarean section and somatic measurements were recorded. The small intestine was harvested and proximal, middle, and distal regions were analyzed for lactase and maltase enzyme activity. Additionally, the uptake of radiolabeled glucose and proline was measured by a standard everted mucosal sleeve technique for each segment. Results were analyzed by Student's paired t test and reported as mean +/- SEM. Nine fetal pairs survived (75%). Small intestinal (SI) length was increased in EGF fetuses (54.8 +/- 1.9 cm) versus control (50.4 +/- 2.7 cm) (P = .02). Lactase activity, reported as UE/g protein, was significantly increased in the proximal segments in the EGF-infused fetuses; maltase was significantly increased in both the proximal and middle segments (P < .05).(ABSTRACT TRUNCATED AT 250 WORDS)
Buchmiller
T L
TL
Department of Pediatric Surgery, UCLA Medical Center 90024.
Shaw
K S
KS
Chopourian
H L
HL
Lloyd
K C
KC
Gregg
J P
JP
Rivera
F A
FA
Lam
M L
ML
Diamond
J M
JM
Fonkalsrud
E W
EW
D000650:Amnion; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D004186:Disaccharidases / Q000187:drug effects* / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D004815:Epidermal Growth Factor / Q000008:administration & dosage*; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy; D005947:Glucose / Q000378:metabolism; D006801:Humans; D015918:Infusion Pumps, Implantable; D007421:Intestine, Small / Q000187:drug effects* / Q000196:embryology / Q000378:metabolism; D011247:Pregnancy; D011392:Proline / Q000187:drug effects / Q000378:metabolism; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage
D011994:Recombinant Proteins; D004815:Epidermal Growth Factor; D011392:Proline; D004186:Disaccharidases; D005947:Glucose